Validated proxies of these brain changes have been incorporated into an influential model of major biomarkers of AD, which summarizes the presence of pathology and neurodegeneration (A/T/N: abnormal levels of Aβ deposition (‘A’), abnormal levels of tau (‘T’) and neurodegeneration (‘N’)21). This evidence concerns the gene MAPT and Alzheimer disease.